Nosocomial Transmission of Delta Hepatitis

  1. LUDWIG A. LETTAU, M.D., M.P.H.;
  2. HOWARD J. ALFRED, M.D.;
  3. RICHARD H. GLEW, M.D.;
  4. HOWARD A. FIELDS, Ph.D.;
  5. MIRIAM J. ALTER, Ph.D.;
  6. RICHARD MEYER, M.D.;
  7. STEPHEN C. HADLER, M.D.; and
  8. JAMES E. MAYNARD, M.D., Ph.D.
  1. Atlanta, Georgia; and Worcester, Massachusetts

    Abstract

    A previously asymptomatic carrier of hepatitis B virus receiving chronic hemodialysis developed acute delta hepatitis. The patient regularly received dialysis treatments on the same machine as a parenteral drug abuser with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis whose serum was strongly positive for delta antibody. The drug abuser had a major bleeding episode that caused extensive environmental contamination 3 months before onset of illness in the index patient. No other patients receiving dialysis or staff members had evidence of delta infection. A surgeon previously infected with hepatitis B from the same parenteral drug abuser also had delta antibody. Testing for delta virus is indicated for both HBsAg-positive parenteral drug abusers and patients with hemophilia receiving chronic hemodialysis. All patients who are HBsAg- and delta-positive should receive dialysis separately from patients who are HBsAg-positive and delta-negative. Susceptible patients on dialysis and staff should receive hepatitis B vaccine to protect against both hepatitis B and delta virus infection.

    Article and Author Information

    • ▸From the Hepatitis Branch, Division of Viral Diseases, Center for Infectious Diseases, Centers for Disease Control, Public Health Service, U.S. Department of Health and Human Services, Atlanta, Georgia; and the Department of Internal Medicine, Worcester Memorial Hospital, Worcester, Massachusetts.

    • ▸Requests for reprints should be addressed to Ludwig A. Lettau, M.D., M.P.H.; Centers for Disease Control, Hepatitis Branch, DVD, Building 6, Room 154; Atlanta, GA 30333.

    « Previous | Next Article »Table of Contents